면역치료제 시장 규모, 점유율 및 성장 분석 : 유형별, 용도별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Immunotherapy Drugs Market size was valued at USD 328.95 Billion in 2024 and is poised to grow from USD 379.28 Billion in 2025 to USD 1184.66 Billion by 2033, growing at a CAGR of 15.3% during the forecast period (2026-2033).

The immunotherapy drugs market is experiencing significant growth driven by the rising prevalence of chronic diseases, notably diabetes, affecting millions worldwide. Companies in this sector are increasingly focusing on innovative product development and strategic partnerships to enhance research efforts. The demand for immunotherapy escalated due to heightened attention during the pandemic, highlighting the efficacy of treatments like monoclonal antibodies in managing severe cases. Regulatory bodies are actively approving more immunotherapy products, further fueling market expansion. Key factors contributing to this growth include the shift towards targeted therapies over conventional treatments, the emergence of biosimilars, lifestyle-related health issues, and a surging demand for monoclonal antibodies. Additionally, heightened collaborations and investments in R&D initiatives by biotechnology and pharmaceutical firms are propelling market advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunotherapy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunotherapy Drugs Market Segments Analysis

Global Immunotherapy Drugs Market is segmented by Type, Route of Administration, Application, Distribution Channel, End User and Region. Based on Type, the market is segmented into Antibody Drugs Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Other Types. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Other Routes of Administration. Based on Application, the market is segmented into Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Other Applications. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Immunotherapy Drugs Market

The immunotherapy drugs market is significantly influenced by the rising incidence of chronic illnesses, including cancer, autoimmune disorders, and infectious diseases. As populations age and lifestyle changes occur, the demand for effective treatment options continues to grow. Immunotherapies offer the promise of potential cures, which further fuels their adoption and market expansion. Moreover, heightened awareness and improved diagnostic capabilities are contributing to the surging demand for these innovative therapies. This combination of factors is essential in shaping the landscape of the immunotherapy pharmaceuticals market, emphasizing the need for advanced treatment solutions in response to widespread health challenges.

Restraints in the Immunotherapy Drugs Market

The immunotherapy drugs market faces significant constraints due to the challenging nature of drug development, which is both complex and costly. The substantial financial investments needed for clinical trials, research, and development create barriers to market entry for new therapies. Additionally, the intricate interactions among immune system components require therapies to be tailored specifically to individual patients or specific patient groups. These challenges collectively hinder the progression of innovative treatments and deter potential new entrants from participating in the market. Consequently, these limitations contribute to a slowdown in overall market growth and the advancement of novel immunotherapeutic options.

Market Trends of the Immunotherapy Drugs Market

The Immunotherapy Drugs market is experiencing a significant shift towards personalized medicine, propelled by advancements in genomics, precision medicine, and genetic engineering. This burgeoning trend focuses on tailoring immunotherapy treatments to individual patients based on their unique genetic compositions, disease histories, and immune profiles, resulting in enhanced therapeutic efficacy and minimized side effects. As clinical trials demonstrate the promising outcomes of personalized immunotherapies, increased investment from businesses is expected to bolster research and development initiatives. This evolution is poised to revolutionize treatment modalities for various conditions, including cancers and autoimmune disorders, thereby driving sustained growth within the immunotherapy sector.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Customer & Buying Criteria Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Pricing Analysis
• Patent Analysis
• Technology Analysis
• Case Study Analysis
• Regulatory Landscape

Immunotherapy Drugs Market, By Type

• Market Overview
• Antibody Drugs
• Inhibitor Drugs
• Interferons & Interleukins
• Cancer Vaccines
• Other Immunotherapy Drugs

Immunotherapy Drugs Market, By Route of Administration

• Market Overview
• Intravenous Route of Administration
• Subcutaneous Route of Administration
• Other Routes of Administration

Immunotherapy Drugs Market, By Application

• Market Overview
• Cancer
• Autoimmune & Inflammatory Diseases
• Hematology
• Osteology
• Neurology
• Other Applications

Immunotherapy Drugs Market, By Distribution Channel

• Market Overview
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Immunotherapy Drugs Market, By End User

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Immunotherapy Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunocore Holdings Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring BV (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments